Sutro Biopharma: Focused on developing next generation antibody drug conjugates (ADCs) and multi-specific antibody-based therapeutics for cancer therapy. The company’s discovery and development efforts are driven by its scalable cell-free protein expression platform (Xpress CF) that enables rapid and systematic evaluation of protein structure-activity relationships. Sutro has three wholly-owned ADCs that are on clinical pathways and three high value collaborations with BMS, Merck, and EMD Serono. FolRα-targeting ADC (STRO-002) Phase 1, anticipated preliminary data in ovarian cancer and EOP1/2 FDA meeting in 2H21. CD74-targeting ADC (STRO-001) Phase 1 dose-expansion to be initiated in 2H21. Pre-clinical data and IND projections for STRO-003 in general cancer anticipated for 2H21. BMS collaboration for CC-99712 (BCMA-targeting ADC) granted orphan drug designation in February 21. IND-enabling tox initiated for Merck collaboration on a cytokine derivative program.